The Psychosocial Burden of the ‘Lazarus Effect’: A Systematic Review of Survivor Guilt, Identity Shift, and Discontinuation Anxiety in Exceptional Responders to Cancer Immunotherapy
Open Access
Abstract
Background/Objectives: Immune checkpoint inhibitors have transformed oncology by inducing unexpected and sustained remissions in some patients; however, this atypical survival may be accompanied by significant psychosocial and existential challenges. The objective was to synthesize the available scientific evidence on the psychosocial burden of the ‘Lazarus Effect’, characterized by survivor guilt, identity shift, and discontinuation anxiety. Methods: A systematic review was conducted following the PRISMA2020 guidelines, based on a preregistered protocol on the OSF. Searches were performed in PubMed, Scopus, Web of Science, and APA PsycINFO using PICOS-based eligibility criteria. Seven primary empirical studies were included, and their methodological quality and risk of bias were assessed using the MMAT 2018. Results: Survivor guilt stems interpersonally from peer deaths and intrapersonally from perceived autonomy loss. Identity shift involves transitioning into an “existential limbo,” re-establishing self-identity while off active treatment. Discontinuation anxiety relates to recurrence fears, absence of curative biomarkers, and uncertainty regarding treatment duration. Interactively, these dimensions drive broader psychosocial burden, including social isolation, “scanxiety,” and a discrepancy between physical recovery and emotional vulnerability. Conclusions: Current evidence—limited to seven heterogeneous studies concentrated in high-income settings—indicates exceptional responses to immunotherapy may involve nuanced psychosocial challenges. Given small sample sizes, melanoma overrepresentation, potential report retrieval bias, and non-standardized assessment tools, findings require cautious interpretation. They offer an exploratory foundation for future research rather than definitive clinical conclusions, supporting preliminary psycho-oncological screening during treatment transitions.Keywords
Funding Information
- Universidad Estatal de Santa Elena [UPSE] (PSIC_01)
This publication has 39 references indexed in Scilit:
- Managing Cancer and Living Meaningfully (CALM) for Patients With Metastatic Cancer and Treatment ResponsePsycho-Oncology, 2026
- Psychological impact of exceptional response in people with advanced cancer: a qualitative explorationJournal of Cancer Survivorship, 2024
- Living in the twilight zone: a qualitative study on the experiences of patients with advanced cancer obtaining long-term response to immunotherapy or targeted therapyJournal of Cancer Survivorship, 2022
- Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLCJournal of Thoracic Oncology, 2021
- A global approach to long‐term follow‐up of targeted and immune‐based therapy in childhood and adolescencePediatric Blood & Cancer, 2021
- Living with and beyond metastatic non-small cell lung cancer: the survivorship experience for people treated with immunotherapy or targeted therapyJournal of Cancer Survivorship, 2021
- Survivorship in immune therapy: Assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligandEuropean Journal of Cancer, 2020
- The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of lifeJournal of Cancer Survivorship, 2020
- Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot studySupportive Care in Cancer, 2019
- An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitorsSupportive Care in Cancer, 2019